Neuroradiology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, University Hospital Careggi, Florence, Italy.
Section of Microbiology and Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Hum Immunol. 2020 Apr;81(4):156-161. doi: 10.1016/j.humimm.2019.11.004. Epub 2019 Nov 15.
The aim of this study was to investigate the potential role of soluble Human Leukocyte Antigen-G (sHLA-G) molecules as biomarkers predicting outcome in acute ischemic stroke (AIS). Serum levels of total sHLA-G (sHLA-G1/HLA-G5) and its soluble isoforms sHLA-G1 and HLA-G5/G6 were measured by enzyme-linked immunosorbent assay (ELISA) in 92 AIS patients and healthy donors (HD). Incidence of hemorrhagic transformation (HT), size of final infarct volume (FIV) and clinical outcome at 3 months were recorded in AIS patients. Detectable serum levels of sHLA-G1/HLA-G5, HLA-G5/G6 and sHLA-G1 were present in a small proportion of AIS patients (26.1%, 17.4% and 16.3%, respectively) and HD (12.5%, 10.7% and 10.7%, respectively) and were more elevated in AIS patients without HT than in those with HT (p < 0.01; p < 0.05; p < 0.01, respectively). HT was less frequent (p < 0.01) in AIS patients with measurable serum concentrations of sHLA-G1/HLA-G5 and HLA-G5/G6. Serum levels of sHLA-G1/HLA-G5 and sHLA-G1 were inversely correlated to FIV (p < 0.02), whereas good outcome was more common (p < 0.01) in AIS patients with detectable serum concentrations of sHLA-G1/HLA-G5. Taken together, these findings suggest that total sHLA-G could exert a protective effect in a subset of AIS patients, irrespective of its soluble isoforms sHLA-G1 and HLA-G5/G6, and indicate that the prognostic value of serum levels of sHLA-G remains to be established.
本研究旨在探讨可溶性人类白细胞抗原-G（sHLA-G）分子作为预测急性缺血性脑卒中（AIS）患者预后的生物标志物的潜在作用。通过酶联免疫吸附试验（ELISA）检测 92 例 AIS 患者和健康对照者（HD）血清中总 sHLA-G（sHLA-G1/HLA-G5）及其可溶性同种型 sHLA-G1 和 HLA-G5/G6 的水平。记录 AIS 患者的出血性转化（HT）发生率、最终梗死体积（FIV）和 3 个月时的临床结局。AIS 患者中仅有一小部分（分别为 26.1%、17.4%和 16.3%）和 HD（分别为 12.5%、10.7%和 10.7%）可检测到 sHLA-G1/HLA-G5、HLA-G5/G6 和 sHLA-G1 的血清水平，且无 HT 的 AIS 患者的 sHLA-G1/HLA-G5 和 HLA-G5/G6 血清水平高于有 HT 的患者（p<0.01;p<0.05;p<0.01）。可检测到 sHLA-G1/HLA-G5 和 HLA-G5/G6 血清浓度的 AIS 患者 HT 发生率较低（p<0.01）。sHLA-G1/HLA-G5 和 sHLA-G1 血清水平与 FIV 呈负相关（p<0.02），而可检测到 sHLA-G1/HLA-G5 血清浓度的 AIS 患者的良好结局更为常见（p<0.01）。综上所述，这些发现表明，总 sHLA-G 可能对 AIS 患者中的一部分发挥保护作用，而与其可溶性同种型 sHLA-G1 和 HLA-G5/G6 无关，并表明 sHLA-G 血清水平的预后价值仍有待确定。
